Ori Biotech

Ori Biotech builds manufacturing technology platforms for cell and gene therapies.

London, UK—Founded 2015—Website

£104MTotal raised

Ori Biotech develops advanced manufacturing technology designed to automate and standardise cell and gene therapy production. The firm works to help developers bring treatments to market at scale.

Founders

Farlan Veraitch

Founder and Chief Scientific Officer

Investors

Series B18 January 2022
£74.0M
Novalis LifeSciencesLead
PC
Puhua Capital
CA
Chimera Abu Dhabi
Amadeus Capital PartnersFollow-on
DV
Delin VenturesFollow-on
Northpond VenturesFollow-on
Octopus VenturesFollow-on
Series A14 October 2020
£23.2M
Northpond VenturesLead
Octopus VenturesLead
Amadeus Capital PartnersFollow-on
DV
Delin VenturesFollow-on
Kindred CapitalFollow-on
Seed8 January 2020
£7.0M
Amadeus Capital Partners
DV
Delin Ventures
Kindred Capital

Funding history

Series B18 January 2022

£74.0M

Ori Biotech secures £74m Series B funding led by Novalis LifeSciences to launch manufacturing platform

Novalis LifeSciences led the Series B round, which will fund team expansion and platform commercialisation.

Series A14 October 2020

£23.2M

Ori Biotech raises £23.2m in Series A funding led by Northpond Ventures and Octopus Ventures

The Series A round was led by Northpond Ventures and Octopus Ventures to help bring the company manufacturing platform to market.

Seed8 January 2020

£7.0M

Ori Biotech secures £7m in seed funding from Amadeus Capital Partners, Delin Ventures and Kindred Capital to commercialise its manufacturing platform.

The seed round was backed by Amadeus Capital Partners, Delin Ventures and Kindred Capital to fund the commercial launch of its manufacturing technology.